These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 35805011)

  • 1. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    Casolino R; Corbo V; Beer P; Hwang CI; Paiella S; Silvestri V; Ottini L; Biankin AV
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
    JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations in pancreatic cancer and potential new therapeutic options.
    Pihlak R; Valle JW; McNamara MG
    Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of
    Ben Khaled N; Hammer K; Ye L; Alnatsha A; Widholz SA; Piseddu I; Sirtl S; Schneider J; Munker S; Mahajan UM; Montero JJ; Griger J; Mayerle J; Reiter FP; De Toni EN
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
    Pimenta JR; Ueda SKN; Peixoto RD
    Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
    Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
    Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
    Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
    Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Medicine for
    Principe DR
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
    Golan T; Javle M
    J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
    Golan T; Hammel P
    J Natl Compr Canc Netw; 2021 Apr; 19(4):469-473. PubMed ID: 33845459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
    Stossel C; Raitses-Gurevich M; Atias D; Beller T; Glick Gorman Y; Halperin S; Peer E; Denroche RE; Zhang A; Notta F; Wilson JM; O'Kane GM; Haimov Talmoud E; Amison N; Schvimer M; Salpeter SJ; Bar V; Zundelevich A; Tirosh I; Tal R; Dinstag G; Kinar Y; Eliezer Y; Ben-David U; Gavert NS; Straussman R; Gallinger SJ; Berger R; Golan T
    Cancer Discov; 2023 Aug; 13(8):1826-1843. PubMed ID: 37449843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.